NEW YORK (MedscapeWire) Mar 13 A broad spectrum fluoroquinolone, gatifloxacin, may change the standard of care for uncomplicated urinary tract infection (UTI), according to a study reported in the March issue of Urology.
"Single-dose and 3-day gatifloxacin were microbiologically and clinically equivalent to 3-day ciprofloxacin for the treatment of acute UTI among women," write George A. Richard, from the University of Florida College of Medicine in Gainesville, and colleagues. "Single-dose gatifloxacin may offer advantages over 3-day fluoroquinolone therapy for uncomplicated UTI by decreasing secondary use of medical resources and improving patient compliance."
In a double-blind, multicenter trial, adult women with acute uncomplicated UTI were randomized to receive either a single 400-mg dose of gatifloxacin (n=442), 200 mg of gatifloxacin daily for 3 days (n=447), or 100 mg ciprofloxacin twice daily for 3 days (n=445).
Patients were assessed within 48 hours before initiation of treatment, by telephone contact on the third day of treatment, and in person 5 to 9 days after treatment. Those patients in whom the infection had been eradicated were also assessed in person at 29 to 42 days after treatment.
Antibiotic treatment eradicated the bacterial pathogen in 90% of patients who received single-dose gatifloxacin, 95% of those who received 3-day gatifloxacin, and 89% of those who received 3-day ciprofloxacin. Clinical efficacy in curing UTI symptoms was 93%, 95%, and 93%, respectivelly…